#RADIUM PROSTATE CANCER TRIAL#

Within the Radium223Insight, 30 patients will be included. The Radium223Insight is a collaborative effort of the Erasmus MC Rotterdam, Radboud UMC Nijmegen and the Franciscus Gasthuis & Vlietland Hospital, Rotterdam. Radium Ra-223 dichloride (radium-223, Xofigo) is a targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. The Radium223Insight study aims to identify biomarkers for early identification of clinical benefit from radium-223 treatment and to better understand immune response during radium-223 treatment in mCRPC patients. Background: Radium-223 is an -emitting radioisotope that induces DNA double-stranded breaks leading to cell death and has demonstrated improvement in overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. In addition, previous studies have shown that radium-223 can induce immune responses, indicating that radium-223 may improve the efficacy of immune checkpoint inhibition.

However, as traditional parameters, including PSA, fail in (early) response evaluation, other parameters are needed to guide treatment planning in mCRPC patients, treated with radium-223. Equality and Human Rights Consultation - NICE TA - Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases.

#RADIUM PROSTATE CANCER TRIAL#

Based on the survival results of a randomized phase 3 trial in 2013, the European Medicines Agency (EMA) has approved radium-223 for the treatment of metastatic castration resistant prostate cancer (mCRPC) with bone metastases only.

Radium prostate cancer